From: Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
Early fibrosis (F0–F1)
Late fibrosis (F2–F3)
Treatment response
•Patients who achieved SVR12 (responders)
103 (73.04%)
38 (26.95%)
•Patients who did not achieve SVR12 (non- responders)
0 (0%)
9 (100%)
p value
< 0.001*